168682-53-9
Chemical Structure
Ezatiostat
Synonym(s): TER199free base; TLK199
- CAS No.: 168682-53-9
- Formula:C27H35N3O6S
- Molecular Weight:529.65
IUPAC Name: ethyl N5-((R)-3-(benzylthio)-1-(((R)-2-ethoxy-2-oxo-1-phenylethyl)amino)-1-oxopropan-2-yl)-L-glutaminate
InChIKey: GWEJFLVSOGNLSS-WPFOTENUSA-N
SMILES: O=C(OCC)[C@@H](C1=CC=CC=C1)NC([C@@H](NC(CC[C@H](N)C(OCC)=O)=O)CSCC2=CC=CC=C2)=O
Biological Activity: Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ezatiostat | 99.71% | Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20 [Content Brief]
- [2]. Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298(1):339-45. [Content Brief]
Keywords
